Johnson & Johnson Exceeds Q4 Expectations with Strong Oncology Demand

Johnson & Johnson (NYSE:JNJ) delivered fourth-quarter results that surpassed Wall Street expectations, driven by robust demand for its cancer treatments and strategic acquisitions. The pharmaceutical giant also provided an upbeat forecast for 2025, projecting full-year sales of $90.9 billion to $91.7 billion and adjusted earnings per share of $10.75 to $10.95, both above analyst estimates.

Revenue for the quarter climbed 5.3% year-over-year to $22.52 billion, bolstered by a remarkable 19% increase in oncology drug sales. The multiple myeloma therapy Darzalex led the charge, with sales surging nearly 21% to over $3 billion.

The company's recent $13.1 billion acquisition of Shockwave Medical contributed $258 million to quarterly revenue, further strengthening its top-line performance.

Adjusted earnings for the quarter came in at $2.04 per share, slightly down from the prior year due to a $0.22 impairment charge linked to the acquisition of V-Wave, a medical device maker. Despite this, the earnings figure beat analyst projections of $2.01.